Growth hormone replacement in patients with Langerhan’s cell histiocytosis

S J Howell, P Wilton, S M Shalet

Abstract

Objectives—To assess the impact of growth hormone on growth and the underlying disease in children with growth hormone deficiency as a result of Langerhan’s cell histiocytosis.

Study design—Retrospective analysis of data from the Kabi (Pharmacia & Upjohn) international growth database (KIGS) for 82 children with Langerhan’s cell histiocytosis treated with recombinant growth hormone.

Results—At the start of treatment the median (10–90th centile) age was 9.0 (5.2 to 14.7) years, with a median height standard deviation score (SDS) of −2.0 (−3.5 to −0.9). The median pretreatment height velocity (measured in cm/year) was 3.6 (0.9 to 6.4); this increased to 8.8 (3.8 to 12.0) in the first year of treatment with growth hormone, and then remained significantly greater than the pretreatment height velocity at 7.3 (4.4 to 9.7) and 7.1 (4.1 to 9.3) cm/year in the second and third years, respectively. The median height SDS increased from −2.0 to −0.8 (−2.3 to 0.6) by the end of three years of treatment. There was no increase in the recurrence rate of the underlying disease and no adverse event could be directly attributed to growth hormone treatment, apart from one case of benign intracranial hypertension that resolved on stopping treatment with growth hormone.

Conclusions—Growth hormone replacement treatment for patients with Langerhan’s cell histiocytosis with growth hormone deficiency is beneficial and safe.

Keywords: growth hormone replacement; Langerhan’s cell histiocytosis; pituitary gland

Langerhan’s cell histiocytosis is a rare disorder of unknown aetiology characterised by histiocytic proliferation.¹ Clinical presentation varies widely from an isolated bone lesion to an aggressive widespread systemic disease. Diabetes insipidus is a relatively common and well recognised manifestation of the disease, with a reported prevalence varying from 10% to 50%.²³ Posterior pituitary dysfunction is thought to be caused by infiltration of the hypothalamic pituitary region and most patients with diabetes insipidus have structural abnormalities in the hypothalamic pituitary region demonstrable by computed tomography.⁴ Anterior pituitary dysfunction is less common and has been described in 1–5% of patients,⁴⁵ ⁷ with growth hormone deficiency being almost invariably present in these patients.

The response to growth hormone in children with Langerhan’s cell histiocytosis and growth hormone deficiency was first reported by Braunstein et al in 1975⁸ when they described five children who had a significant improvement in height velocity during two years of treatment with growth hormone. There are only two other reports about the treatment of growth hormone deficiency due to Langerhan’s cell histiocytosis,⁹ ¹⁰ each describing one patient whose growth rate improved with growth hormone replacement. No large cohort of patients with Langerhan’s cell histiocytosis treated with growth hormone replacement has previously been reported. Examination of the effects of growth hormone treatment in patients with Langerhan’s cell histiocytosis is important to ensure that it is safe and effective.

We reviewed 82 patients with growth hormone deficiency and Langerhan’s cell histiocytosis who were enrolled in the Kabi (Pharmacia & Upjohn) international growth database (KIGS) between 1988 and 1995. All were treated with recombinant growth hormone. We calculated the growth rates of patients before and for the first three years after starting treatment with growth hormone and compared these with the growth response of children with growth hormone deficiency from other causes. We also recorded the incidence of adverse events.

Patients and methods

The data were collected retrospectively from the KIGS database that was set up in 1987 to monitor the progress of children treated with recombinant growth hormone (Somatonom or Genotropin; Pharmacia & Upjohn, Stockholm, Sweden). Cross sectional data were available for 82 patients with Langerhan’s cell histiocytosis at the start of treatment, 61 after one year of treatment, 40 after two years, and 30 after three years. Age, height (in cm), and height standard deviation score (SDS) (calculated using the Tanner standards) were recorded for all patients. Height velocity, measured in cm/year, was calculated for 47 of the 82 patients before treatment and in all patients after the start of treatment with growth hormone. The target height was estimated in boys as 0.5 (mother’s height + father’s height + 13) and in girls as 0.5 (mother’s height + father’s height − 13). The actual height SDS minus the target height SDS was calculated for most patients (76 pretreatment, 56 at one year, 36 at two years, and 26 at three

Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK
S J Howell
S M Shalet

KIGS/KIMS, Pharmacia & Upjohn, Stockholm, Sweden (on behalf of the International Board of KIGS)
P Wilton

Correspondence to: Professor Shalet.

Accepted 3 February 1998
Table 1 Baseline characteristics

| Number (%) | Male | 55 (67.1) |
| Number (%) | Female | 27 (32.9) |
| Median (10th, 90th centile) age at diagnosis of LCH (years) (n = 50) | 2.9 (0.6, 8.4) |
| Median (10th, 90th centile) age at start of GH (years) (n = 82) | 9.0 (5.2, 14.7) |
| Median (10th, 90th centile) height SDS (n = 82) | −2.0 (−3.5, −0.9) |
| Median (10th, 90th centile) height − target height SDS (n = 76) | −1.8 (−3.0, −0.5) |
| Height velocity in cm/year (n = 47) | 3.6 (0.9, 6.4) |
| Number (%) TSH deficient (n = 79) | 14 (17.7) |
| Number (%) ACTH deficient (n = 78) | 8 (10.3) |
| Number (%) LH, FSH deficient (n = 57) | 6 (10.5) |
| Number (%) with diabetes insipidus (n = 79) | 53 (67.1) |

n, number of patients for whom information was available. LCH, Langerhan's cell histiocytosis; GH, growth hormone treatment; TSH, thyroid stimulating hormone; ACTH, adrenocorticotrophin hormone; LH, luteinising hormone; FSH, follicle stimulating hormone.

Results

The diagnosis of growth hormone deficiency was based on auxological criteria (height SDS, height velocity) along with the growth hormone response to standard stimulation tests, insulin induced hypoglycaemia and arginine being the most commonly used agents. The median (10–90th centile) growth hormone peak during provocative testing was 2.1 µg/l (0.4–5.0) (conversion to IU: 1 µg/l = 3 mIU/l) in the group as a whole and 2.0 µg/l (0.2–5.3) in the 17 prepubertal patients followed longitudinally. All patients were subsequently treated with growth hormone at a median dose of 0.17 mg/kg/week (0.14–0.26).

Table 2 Median (10th, 90th centile) height SDS, height − target height SDS, and height velocity (cm/year) before and during growth hormone replacement treatment

<table>
<thead>
<tr>
<th>Position</th>
<th>Height SDS</th>
<th>Height − target height SDS</th>
<th>Height velocity (cm/year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pretreatment</td>
<td>−2.0 (−3.5, −0.9)</td>
<td>−1.8 (−3.0, −0.5)*</td>
<td>3.6 (0.9, 6.4)</td>
</tr>
<tr>
<td>1 year (n = 61)</td>
<td>−1.8 (−3.2, −0.1)</td>
<td>−1.4 (−2.6, −0.1)</td>
<td>8.8 (3.8, 12.0)</td>
</tr>
<tr>
<td>2 years (n = 40)</td>
<td>−1.5 (−3.0, 0.1)</td>
<td>−1.3 (−2.6, 0.2)</td>
<td>7.3 (4.4, 9.7)</td>
</tr>
<tr>
<td>3 years (n = 30)</td>
<td>−0.6 (−2.6, 0.4)</td>
<td>−1.1 (−2.3, 0.6)</td>
<td>7.1 (4.1, 9.3)</td>
</tr>
<tr>
<td>Longitudinal (n = 17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pretreatment</td>
<td>−2.0 (−4.1, −1.1)</td>
<td>−2.4 (−3.9, −1.0)*</td>
<td>4.5 (0.9, 6.5)</td>
</tr>
<tr>
<td>1 year</td>
<td>−1.6 (−3.2, −0.4)</td>
<td>−2.1 (−3.3, −0.4)</td>
<td>8.9 (5.6, 13.1)</td>
</tr>
<tr>
<td>2 years</td>
<td>−1.1 (−2.5, 0.2)</td>
<td>−1.7 (−2.6, 0.1)*</td>
<td>7.3 (3.7, 9.9)</td>
</tr>
<tr>
<td>3 years</td>
<td>−0.8 (−2.6, 0.5)</td>
<td>−1.5 (−2.5, 0.0)*</td>
<td>7.3 (4.2, 9.3)</td>
</tr>
</tbody>
</table>

*Data from 76 patients; †data from 47 patients; ‡data from 15 patients; §data from 11 patients.

The median height velocity in cm/year and height SDS are both reduced, in keeping with a diagnosis of growth hormone deficiency. Diabetes insipidus was present in 67% of patients, whereas other pituitary hormone deficiencies occurred less often. All patients were receiving adequate replacement treatment for other hormone deficiencies before starting growth hormone treatment.

Pubertal status was recorded in 60 of the 82 patients at baseline and eight children had entered puberty. Eleven of 46, nine of 34, and 10 of 27 children had entered puberty, respectively, at one year, 34 at two years, and 27 at three years. Entry into puberty was defined as breast stage 2 for girls and a testicular volume of 4 ml for boys.

A proportion of the children had entered puberty by the end of the three years of study. Therefore, longitudinal data from a subset of 17 children who remained prepubertal throughout were analysed separately. Height SDS and height velocity were recorded in all patients at all times, except for six patients whose height velocity was not calculated before treatment. The target height was estimated in all but two subjects and therefore the height SDS minus the target height SDS was calculated for 15 patients at zero, one, two, and three years.

Analysis of the patients according to their exposure to cranial irradiation or chemotherapy showed no significant difference in baseline growth parameters between those who had received radiotherapy or drug treatment and those who had not.

The response to growth hormone treatment has been reported in other patients with organic or idiopathic growth hormone

Howell, Wilson, Shalet

Downloaded from http://adc.bmj.com/ on June 20, 2017 - Published by group.bmj.com
Table 3 Height velocity (cm/year) in patients with idiopathic growth hormone deficiency and growth hormone deficiency associated with Langerhan’s cell histiocytosis

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Cross sectional (n = 82)</th>
<th>Longitudinal (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st year of treatment</td>
<td>8.8 (5.8, 12.9)*</td>
<td>8.8 (3.8, 12.0)†</td>
</tr>
<tr>
<td>2nd year of treatment</td>
<td>6.7 (4.7, 9.4)</td>
<td>7.3 (4.4, 9.7)</td>
</tr>
</tbody>
</table>

Values are median (10th, 90th centiles). * Data from 47 patients; † data from 11 patients.

Discussion

We have described a large group of patients deficient in growth hormone with Langerhan’s cell histiocytosis who were treated with growth hormone. Both cross sectional and longitudinal data show a poor median height velocity pretreatment, which markedly improved after treatment with growth hormone. This improved rate of growth was maintained for at least three years and resulted in an increase in height SDS.

There are potential problems in using data obtained from an international database such as KIGS. The reliability of such data is dependent on accurate diagnosis and reporting by many different investigators. The diagnosis of Langerhan’s cell histiocytosis, however, was not revised in any of the study patients during a mean follow up of over five years. There was also documented evidence of growth hormone deficiency in all patients and diabetes insipidus in two thirds of the patients. A large proportion of the 20 children who received cranial irradiation received radiotherapy to a skull Langerhan’s cell histiocytosis lesion with a dose sufficiently low to exclude the possibility of radiation induced growth hormone deficiency. Furthermore, all but two of the 20 cranially irradiated children had diabetes insipidus, a complication that has never been documented after irradiation. Growth hormone deficiency and diabetes insipidus are recognised complications of Langerhan’s cell histiocytosis and these hormone deficiencies could not be attributed to their treatment or to any other cause during prolonged follow up. It therefore seems reasonable to conclude that the diagnosis of Langerhan’s cell histiocytosis was correct in most patients and that the cause of their growth hormone deficiency was the disease itself.

The safety data are similarly dependent on the accurate reporting of the side effects of treatment. However, although trivial side effects may not be fully documented, it is extremely unlikely that any significant adverse events would not be reported. It is the occurrence of serious side effects and, in particular, the recurrence or progression of Langerhan’s cell histiocytosis that is of greatest importance in these children, and it is likely that in this respect our data are accurate. Thus although there are fundamental problems inherent in analysing data from any large international database, it is unlikely that any errors in data collection would significantly alter our conclusions. The safety data are critically important for the clinician and there is no realistic possibility that such information could ever be collected from a single centre. Thus only a large international database, with all its inherent limitations, can truly address this issue.

The rate of growth in response to growth hormone replacement in patients with Langerhan’s cell histiocytosis is similar to that observed in children with idiopathic growth hormone deficiency.11 Direct comparison of the results of all 82 children is difficult because of the differences in patient characteristics. Twenty six per cent of the patients with Langerhan’s cell histiocytosis had entered puberty by the end of the second year, compared with only nine (3%) of the idiopathic group. Puberty, however, is not the only factor that influences the initial response to growth hormone. Ranke and Guilbaud12 found that the first year height velocity was negatively corre-
Age and DHT values are for the start of the first year. Growth hormone dose and injection frequency are median values based on the whole of the first year. Table 4 shows a comparison of the factors that influence the observed response to growth hormone in the first year in our group of children with Langerhan’s cell histiocytosis and the idiopathic growth hormone deficiency group. The 82 children with Langerhan’s cell histiocytosis were older and had a lower median DHT than the patients with idiopathic growth hormone deficiency. Thus when comparing the two groups, any growth advantage conferred on the patients with Langerhan’s cell histiocytosis by the higher incidence of puberty is likely to be offset by their greater chronological age and lower DHT at the start of treatment. It is therefore likely that any bias introduced by the different baseline characteristics is not great. This is confirmed when the subset of 17 prepubertal children are compared with the idiopathic growth hormone deficiency group. The influential factors were almost identical, whereas the growth response to growth hormone was at least as good in the patients with Langerhan’s cell histiocytosis as in the idiopathic growth hormone deficiency group.

The data for patients with Langerhan’s cell histiocytosis also compare favourably with those obtained in children with organic growth hormone deficiency. Cross sectional data from 723 children with central nervous system tumours12 and 103 children treated for acute lymphoblastic leukaemia13 have previously been analysed from the KIGS database. The median pretreatment height velocity in these groups was similar to that in the Langerhan’s cell histiocytosis cohort. First, second, and third year height velocities, however, were lower than those observed in the Langerhan’s cell histiocytosis cohort, suggesting there may be a better growth response to growth hormone replacement in patients with Langerhan’s cell histiocytosis than in those irradiated for acute lymphoblastic leukaemia or central nervous system malignancy.

Adverse events that could be attributed to growth hormone were minimal. Spontaneous recurrence of Langerhan’s cell histiocytosis has previously been reported at varying frequencies and times after initial diagnosis. Gadner and colleagues14 found a recurrence rate of 12–42% during a median follow up of almost seven years. Kilpatrick and colleagues15 studied 263 paediatric and adult cases of Langerhan’s cell histiocytosis over a mean time of 12 years and found a recurrence rate of 17%, but a much higher frequency (48%) in patients with diabetes insipidus. Therefore, considering the high incidence of diabetes insipidus in our cohort, a definite recurrence of the disease in only three, and at the most five, of the 82 patients during a three year period does not represent an excessively high recurrence rate.

One patient developed a central nervous system malignancy preceded by intracranial hypotension. It is possible that the symptoms and signs on which the diagnosis of benign intracranial hypertension was based were in fact due to the developing tumour, although the absence of abnormalities on the scan and the clinical response to stopping growth hormone would argue against this. Benign intracranial hypertension is a recognised side effect of growth hormone replacement, which usually improves on stopping treatment.16 Central nervous system malignancies, however, have not been shown to occur with increased frequency in patients receiving growth hormone.16,17 None of the other adverse events has previously been associated with growth hormone replacement and it seems unlikely that their occurrence was related to the treatment. Thus the use of growth hormone in this group of patients with growth hormone deficiency does not appear to be associated with any unwanted side effects other than the one case of benign intracranial hypertension, which resolved on stopping treatment with growth hormone.

Thus we have shown that the growth response to growth hormone replacement in children with Langerhan’s cell histiocytosis is at least as good as that seen in other patients with growth hormone deficiency. No increase has been shown in the activity of the underlying disease while receiving growth hormone, and no excess of other adverse events attributable to growth hormone treatment. We can therefore conclude, based on the data obtained from a substantial cohort of patients, that growth hormone treatment of patients with Langerhan’s cell histiocytosis and growth hormone deficiency is beneficial, in terms of improved growth rate, and is also safe.

Declaration of interest: Some of Professor Shalet’s clinical research activities are supported financially by pharmaceutical companies producing growth hormone.


Growth hormone replacement in patients with Langerhan’s cell histiocytosis

S J Howell, P Wilton and S M Shalet

Arch Dis Child 1998 78: 469-473
doi: 10.1136/adc.78.5.469

Updated information and services can be found at:
http://adc.bmj.com/content/78/5/469

These include:

References
This article cites 14 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/78/5/469#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Hypertension (369)
- Child health (3922)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/